​
​

Astria Therapeutics (ATXS) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChartTranscripts

ATXS Stock Forecast

Astria Therapeutics stock forecast is as follows: an average price target of $22.50 (represents a 130.77% upside from ATXS’s last price of $9.75) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

ATXS Price Target

The average price target for Astria Therapeutics (ATXS) is $22.50 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $25.00 to $20.00. This represents a potential 130.77% upside from ATXS's last price of $9.75.

ATXS Analyst Ratings

Buy

According to 3 Wall Street analysts, Astria Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for ATXS stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Astria Therapeutics Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 21, 2024Hartaj SinghOppenheimer$25.00$9.59160.69%156.41%
Mar 26, 2024Hartaj SinghOppenheimer$29.00$14.12105.38%197.44%
Dec 19, 2022-H.C. Wainwright$20.00$11.8169.35%105.13%
Row per page
Go to

The latest Astria Therapeutics stock forecast, released on May 21, 2024 by Hartaj Singh from Oppenheimer, set a price target of $25.00, which represents a 160.69% increase from the stock price at the time of the forecast ($9.59), and a 156.41% increase from ATXS last price ($9.75).

Astria Therapeutics Price Target by Period

1M3M12M
# Anlaysts--2
Avg Price Target--$27.00
Last Closing Price$9.75$9.75$9.75
Upside/Downside-100.00%-100.00%176.92%

In the current month, the average price target of Astria Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Astria Therapeutics's last price of $9.75. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Sep 25, 2024Cowen & Co.BuyBuyHold
Aug 13, 2024OppenheimerOutperformOutperformHold
Jul 29, 2024Cowen & Co.-BuyInitialise
May 21, 2024OppenheimerOutperformOutperformHold
Mar 26, 2024OppenheimerOutperformOutperformHold
Dec 19, 2022Piper SandlerBuyBuyHold
Row per page
Go to

Astria Therapeutics's last stock rating was published by Cowen & Co. on Sep 25, 2024. The company gave ATXS a "Buy" rating, the same as its previous rate.

Astria Therapeutics Financial Forecast

Astria Therapeutics Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
Revenue-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
# Analysts-------
Surprise %-------

Astria Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. ATXS's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Astria Therapeutics EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
EBITDA-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
Surprise %-------

undefined analysts predict ATXS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Astria Therapeutics's previous annual EBITDA (undefined) of $NaN.

Astria Therapeutics Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
Net Income-------
Avg Forecast$-25.14M$-24.85M$-24.85M$-24.57M$-24.06M$-23.82M$-20.81M
High Forecast$-25.14M$-24.85M$-24.85M$-23.50M$-17.19M$-23.82M$-20.81M
Low Forecast$-25.14M$-24.85M$-24.85M$-25.11M$-28.65M$-23.82M$-20.81M
Surprise %-------

Astria Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ATXS's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Astria Therapeutics SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
SG&A-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
Surprise %-------

Astria Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to ATXS last annual SG&A of $NaN (undefined).

Astria Therapeutics EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
EPS-------
Avg Forecast$-0.45$-0.44$-0.44$-0.43$-0.43$-0.42$-0.37
High Forecast$-0.45$-0.44$-0.44$-0.42$-0.30$-0.42$-0.37
Low Forecast$-0.45$-0.44$-0.44$-0.44$-0.51$-0.42$-0.37
Surprise %-------

According to undefined Wall Street analysts, Astria Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ATXS previous annual EPS of $NaN (undefined).

Astria Therapeutics Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
ANTXAN2 Therapeutics$1.06$8.75725.47%Buy
AVTEAerovate Therapeutics$2.67$13.00386.89%Hold
OPTOpthea$3.26$14.00329.45%Buy
ANEBAnebulo Pharmaceuticals$1.52$6.00294.74%Buy
FENCFennec Pharmaceuticals$4.28$15.75267.99%Buy
ACRVAcrivon Therapeutics$6.38$21.83242.16%Buy
OLMAOlema Pharmaceuticals$8.72$28.50226.83%Buy
LRMRLarimar Therapeutics$6.38$20.33218.65%Buy
RZLTRezolute$4.95$13.50172.73%Buy
ANABAnaptysBio$19.97$52.00160.39%Buy
MLYSMineralys Therapeutics$12.86$30.00133.28%Buy
ATXSAstria Therapeutics$9.75$22.50130.77%Buy
ADAGAdagene$2.22$5.00125.23%Buy
IRONDisc Medicine$59.55$72.5021.75%Buy

ATXS Forecast FAQ

Is Astria Therapeutics a good buy?

Yes, according to 3 Wall Street analysts, Astria Therapeutics (ATXS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of ATXS's total ratings.

What is ATXS's price target?

Astria Therapeutics (ATXS) average price target is $22.5 with a range of $20 to $25, implying a 130.77% from its last price of $9.75. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Astria Therapeutics stock go up soon?

According to Wall Street analysts' prediction for ATXS stock, the company can go up by 130.77% (from the last price of $9.75 to the average price target of $22.5), up by 156.41% based on the highest stock price target, and up by 105.13% based on the lowest stock price target.

Can Astria Therapeutics stock reach $15?

ATXS's average twelve months analyst stock price target of $22.5 supports the claim that Astria Therapeutics can reach $15 in the near future.

What are Astria Therapeutics's analysts' financial forecasts?

Astria Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-68.687M (high $-61.813M, low $-73.271M), average SG&A $0 (high $0, low $0), and average EPS is $-1.216 (high $-1.094, low $-1.297). ATXS's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-99.415M (high $-98.347M, low $-99.95M), average SG&A $0 (high $0, low $0), and average EPS is $-1.76 (high $-1.741, low $-1.769).